DOCSLIB.ORG

Federal Register/Vol. 68, No. 71/Monday, April 14, 2003/Notices

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Federal Register/Vol. 68, No. 71/Monday, April 14, 2003/Notices Federal Register / Vol. 68, No. 71 / Monday, April 14, 2003 / Notices 17953 CFR Number of Responses per Avg burden per Total annual reference Data collection respondents respondent response (in hrs.) burden (in hrs.) 73.6 (c–e) Request for exemption .............................. 17 1 70/60 20 73.14 ........ Transfer of select agent ............................ 1,000 5 1.75 8,750 73.6 (a)(2) Clinical and diagnostic laboratory exemp- 1,000 4 1 4,000 tion report. 73.7(i) ....... Notification of inactivation .......................... 6 1 30/60 3 73.8(g) ..... Request expedited review ......................... 6 1 30/60 3 73.10(b) ... Documentation of self-inspection .............. 1,000 1 1 1,000 73.13(f) .... Documentation of training ......................... 1,000 1 2 8,700 73.18 ........ Administrative review ................................. 14 1 4 56 73.15(d) ... Ensure secure recordkeeping system ....... 1,000 1 30/60 4,000 Total .. .................................................................... 1,000 ................................ ................................ 34,804 Dated: April 7, 2003. and other comments should be patients not improved by estrogen Thomas Bartenfeld, identified with Docket No. 76N–0377 alone.’’ Acting Associate Director for Policy, Planning and submitted to the Dockets In the Federal Register of December and Evaluation, Centers for Disease Control Management Branch (HFA–305), Food 17, 1998 (63 FR 69631), FDA withdrew and Prevention. and Drug Administration, 5630 Fishers approval of estrogen-containing drugs [FR Doc. 03–9019 Filed 4–11–03; 8:45 am] Lane, rm. 1061, Rockville, MD 20852. A insofar as they are indicated for BILLING CODE 4163–18–P request for an opinion on the postpartum breast engorgement because applicability of this notice to a specific estrogens have not been shown to be drug product should be directed to the safe for this use. That Federal Register DEPARTMENT OF HEALTH AND Division of New Drugs and Labeling notice included, among others, four of HUMAN SERVICES Compliance (HFD–310), Center for Drug the five NDAs listed above. (NDA 11– Evaluation and Research, Food and 267 was not included because the drug Food and Drug Administration Drug Administration, 5600 Fishers product covered by that application, [Docket Nos. 78N–0377 and 98P–1041; DESI Lane, Rockville, MD 20857. Halodrin Tablets, was not labeled for 7661] use for postpartum breast engorgement.) FOR FURTHER INFORMATION CONTACT: Given this December 17, 1998 notice, David T. Read, Center for Drug Certain Estrogen-Androgen the following discussion relates only to Evaluation and Research (HFD–7), Food Combination Drugs; Drugs for Human the second indication found safe and Use; Drug Efficacy Study and Drug Administration, 5600 Fishers effective in the 1972 notice, i.e., ‘‘for the Implementation; Amendment and Lane, Rockville, MD 20857, 301–594– menopausal syndrome in patients not Opportunity for Hearing 2041. improved by estrogen alone.’’ SUPPLEMENTARY INFORMATION: In the Federal Register of September AGENCY: Food and Drug Administration, 29, 1976 (41 FR 43112), the agency HHS. I. Background announced that the menopausal ACTION: Notice. In a notice published in the Federal indication for combination drugs SUMMARY: The Food and Drug Register of September 8, 1972 (37 FR containing an estrogen and an androgen Administration (FDA) is amending a 18225), FDA announced its evaluation was revised to read as follows: previous Federal Register notice to of the various indications claimed for Moderate to severe vasomotor symptoms the following combination drugs that associated with the menopause in those reclassify certain estrogen-androgen patients not improved by estrogen alone. combination drugs as lacking contain an estrogen and an androgen: (There is no evidence that estrogens are substantial evidence of effectiveness for 1. Halodrin Tablets (NDA 11–267), effective for nervous symptoms or depression the treatment of moderate to severe containing fluoxymesterone and ethinyl which might occur during menopause, and vasomotor symptoms associated with estradiol; they should not be used to treat these the menopause in those patients not 2. Tylosterone Injection (NDA 8–099), conditions.) 41 FR 43112 at 43113. (emphasis improved by estrogen alone. The agency containing diethylstilbestrol and in original) This action was taken as one part of is taking this action because for this methyltestosterone; a large agency undertaking with respect indication there is not substantial 3. Tylosterone Tablets (NDA 7–661), to the labeling (patient-directed as well evidence of the contribution of each containing diethylstilbestrol and as physician-directed) for all estrogen- component to the effectiveness of these methyltestosterone; containing drug products. The following combination drugs. FDA is offering an 4. Tace with Androgen Capsules documents were also published in the opportunity for a hearing to persons (NDA 10–597), containing Federal Register of September 29, 1976: affected by this action. chlorotrianisene and (1) 41 FR 43110 (DESI 2238; Certain DATES: Requests for hearings are due on methyltestosterone; Preparations for Vaginal Use); (2) 41 FR or before May 14, 2003. Data in support 5. Deladumone Injection and 43114 (DESI 1543; Certain Estrogen- of hearing requests are due June 13, Deladumone OB Injection (NDA 9–545), Containing Drugs for Oral or Parenteral 2003. containing testosterone enanthate and Use); (3) 41 FR 43117 (DESI 740, 1543, ADDRESSES: Communications in estradiol valerate. 2238, and 7661; Physician Labeling and response to this notice should be As announced in that 1972 notice, Patient Labeling for Estrogens for identified with the reference number FDA found these drugs to be safe and General Use); and (4) 41 FR 43108 (a DESI 7661 and directed to the attention effective for the ‘‘prevention of proposed rule that would require certain of the appropriate office named below. postpartum breast engorgement and ‘‘for patient-directed labeling for estrogens A request for hearing, supporting data, the menopausal syndrome in those for general use). VerDate Jan<31>2003 14:06 Apr 11, 2003 Jkt 200001 PO 00000 Frm 00048 Fmt 4703 Sfmt 4703 E:\FR\FM\14APN1.SGM 14APN1 17954 Federal Register / Vol. 68, No. 71 / Monday, April 14, 2003 / Notices The five applications listed below (59 FR 9989), respectively. The agency improved by estrogen alone. The use of were approved on the basis of the 1976 withdrew approval of NDA 7–661 these combination drug products for any notice, and their approvals are (Tylosterone Tablets) and NDA 8–099 other use, including but not limited to withdrawn in a notice published (Tylosterone Injection), both containing the treatment of other menopausal elsewhere in today’s issue of the diethylstilbestrol and symptoms, will not be considered in Federal Register: methyltestosterone, and NDA 9–545 this proceeding. The effectiveness of 1. NDA 17–968 and ANDA 85–603 (Deladumone OB Injection and estrogen-androgen combination (testosterone cypionate 50 milligrams/ Deladumone Injection, each containing products for indications not covered by milliliter (mg/mL) and estradiol testosterone enanthate and estradiol this proceeding should be addressed cypionate 2 mg/mL injection). valerate) in a notice published in the through the new drug application 2. ANDA 85–860 and ANDA 86–423 Federal Register of October 29, 1998 (63 process. (testosterone enanthate 180 mg/mL and FR 58053). estradiol valerate 8 mg/mL injection). In response to the notice of October II. The Safety and Effectiveness of 3. ANDA 85–865 (testosterone 29, 1998, on November 24, 1998, Solvay Estrogen-Androgen Combination Drug enanthate 90 mg/mL and estradiol Pharmaceuticals submitted a citizen Products for the Treatment of valerate 4 mg/mL injection). petition (Docket No. 98P–1041) Vasomotor Symptoms Associated With In 1981, the Center for Drug requesting that FDA determine that the Menopause in Patients Not Improved Evaluation and Research (CDER) (then products covered by the three by Estrogen Alone the Bureau of Drugs) determined in applications withdrawn in the October The agency took a renewed interest in response to requests from the sponsors 21, 1998, notice were not withdrawn for estrogen-androgen combination drug that the effectiveness finding of the 1976 reasons of safety or effectiveness. As products when concerns were raised DESI 7661 Federal Register notice could FDA is doing for the five estrogen- about the effect of androgens in be applied to two combination drug androgen combination products whose lowering high-density lipoproteins products that were not listed in the 1976 approvals are being withdrawn in a (Refs. notice, but were being marketed at the notice published elsewhere in today’s 1 and 2). It is believed that oral time: (1) Conjugated estrogens and issue of the Federal Register, the agency androgens can reverse the favorable methyltestosterone and (2) esterified is deferring to the outcome of this impact of estrogen on lipoproteins (Ref. estrogens and methyltestosterone. Based proceeding to amend the 1976 notice 3). Other safety concerns were on this finding, FDA filed (i.e., accepted the determination of whether the for review) abbreviated new drug virilization (Refs. 4 and 5) and possible products covered by the three liver toxicity (Refs. 6, 7, and 8). applications (ANDAs) for these drug applications named in Solvay’s petition products. Wyeth-Ayerst submitted FDA concluded that the negative were withdrawn for reasons of safety or effects
Load more

Recommended publications
  • Depo-Estradiol (Estradiol Cypionate) Injection
    Market Applicability Market DC GA KY MD NJ NY WA Applicable X X X X X X NA Depo-Estradiol (estradiol cypionate) injection Override(s) Approval Duration Prior Authorization 1 year Medications Depo-Estradiol (estradiol cypionate) injection APPROVAL CRITERIA Requests for Depo-Estradiol (estradiol cypionate) injection may be approved when the following criteria are met: I. Individual is using to treat moderate to severe vasomotor symptoms associated with menopause; OR II. Individual has been diagnosed with hypoestrogenism due to hypogonadism; OR III. Individual has a diagnosis of gender dysphoria or gender identity disorder (WPATH 2012, Endocrine Society 2017) ; AND IV. Individual is 16 years of age or older; AND V. The goal of treatment is male-to-female gender reassignment. Requests for Depo-Estradiol (estradiol cypionate) injection may not be approved for any of the following: I. Individual has undiagnosed abnormal genital bleeding; OR II. Individual has known or suspected cancer of the breast; OR III. Individual has known or suspected estrogen-dependent neoplasia; OR IV. Individual has active deep vein thrombosis, pulmonary embolism or history of these conditions; OR V. Individual has active or recent (within the past year) arterial thromboembolic disease (such as stroke or myocardial infarction); OR VI. Individual has liver dysfunction or disease. PAGE 1 of 2 02/24/2020 New Program Date 02/24/2020 CRX-ALL-0519-20 This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.
    [Show full text]
  • PPE Requirements Hazardous Drug Handling
    This document’s purpose is only to provide general guidance. It is not a definitive interpretation for how to comply with DOSH requirements. Consult the actual NIOSH hazardous drugs list and program regulations in entirety to understand all specific compliance requirements. Minimum PPE Required Minimum PPE Required Universal (Green) - handling and disposed of using normal precautions. PPE Requirements High (Red) - double gloves, gown, eye and face protection in Low (Yellow) - handle at all times with gloves and appropriate engineering Hazardous Drug Handling addition to any necessary controls. engineering controls. Moderate (Orange) -handle at all times with gloves, gown, eye and face protection (with splash potential) and appropirate engineering controls. Tablet Open Capsule Handling only - Contained Crush/Split No alteration Crush/Split Dispensed/Common Drug Name Other Drug Name Additional Information (Formulation) and (NIOSH CATEGORY #) Minimum PPE Minimum PPE Minimum PPE Minimum PPE Required required required required abacavir (susp) (2) ziagen/epzicom/trizivir Low abacavir (tablet) (2) ziagen/epzicom/trizivir Universal Low Moderate acitretin (capsule) (3) soriatane Universal Moderate anastrazole (tablet) (1) arimidex Low Moderate High android (capsule) (3) methyltestosterone Universal Moderate apomorphine (inj sq) (2) apomorphine Moderate arthotec/cytotec (tablet) (3) diclofenac/misoprostol Universal Low Moderate astagraf XL (capsule) (2) tacrolimus Universal do not open avordart (capsule) (3) dutasteride Universal Moderate azathioprine
    [Show full text]
  • PEMD-91-12BR Off-Label Drugs: Initial Results of a National Survey
    11 1; -- __...._-----. ^.-- ______ -..._._ _.__ - _........ - t Ji Jo United States General Accounting Office Washington, D.C. 20648 Program Evaluation and Methodology Division B-242851 February 25,199l The Honorable Edward M. Kennedy Chairman, Committee on Labor and Human Resources United States Senate Dear Mr. Chairman: In September 1989, you asked us to conduct a study on reimbursement denials by health insurers for off-label drug use. As you know, the Food and Drug Administration designates the specific clinical indications for which a drug has been proven effective on a label insert for each approved drug, “Off-label” drug use occurs when physicians prescribe a drug for clinical indications other than those listed on the label. In response to your request, we surveyed a nationally representative sample of oncologists to determine: . the prevalence of off-label use of anticancer drugs by oncologists and how use varies by clinical, demographic, and geographic factors; l the extent to which third-party payers (for example, Medicare intermediaries, private health insurers) are denying payment for such use; and l whether the policies of third-party payers are influencing the treatment of cancer patients. We randomly selected 1,470 members of the American Society of Clinical Oncologists and sent them our survey in March 1990. The sam- pling was structured to ensure that our results would be generalizable both to the nation and to the 11 states with the largest number of oncologists. Our response rate was 56 percent, and a comparison of respondents to nonrespondents shows no noteworthy differences between the two groups.
    [Show full text]
  • Pms-ESTRADIOL VALERATE INJECTION
    PRODUCT MONOGRAPH Prpms-ESTRADIOL VALERATE INJECTION Estradiol Valerate 10 mg/mL Estrogen PHARMASCIENCE INC. Date of Revision: 6111 Royalmount Avenue, Suite 100 June 30, 2009 Montreal, Quebec H4P 2T4 Control Number: 120632 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION……………………………...3 SUMMARY PRODUCT INFORMATION……………………………………….3 INDICATIONS AND CLINICAL USE…………………………………………...3 CONTRAINDICATIONS…………………………………………………………4 WARNINGS AND PRECAUTIONS…………………………………….……….5 ADVERSE REACTIONS………………………………………………………...13 DRUG INTERACTIONS………………………………………………………...15 DOSAGE AND ADMINISTRATION…………………………………………...17 OVERDOSAGE………………………………………………………………….19 ACTION AND CLINICAL PHARMACOLOGY……………………………….19 STORAGE AND STABILITY…………………………………………………...22 DOSAGE FORMS, COMPOSITION AND PACKAGING……………………..22 PART II: SCIENTIFIC INFORMATION…………………………………………….23 PHARMACEUTICAL INFORMATION………………………………………...23 CLINICAL TRIALS……………………………………………………………...24 DETAILED PHARMACOLOGY………………………………………………..24 REFERENCES…………………………………………………………………...25 PART III: CONSUMER INFORMATION……………………………………………………27 2 PRODUCT MONOGRAPH Prpms- ESTRADIOL VALERATE INJECTION (Estradiol Valerate) 10 mg/mL PART I: HEALTH PROFESSIONAL INFORMATION SUMMARY PRODUCT INFORMATION Route of Dosage Form / Strength Clinically Relevant Nonmedicinal Administration Ingredients Intramuscular Injection / 10 mg/mL Sesame Oil For a complete listing see Dosage Forms, Composition and Packaging section. INDICATIONS AND CLINICAL USE pms-ESTRADIOL VALERATE INJECTION is indicated in the treatment of: I. amenorrhea (primary
    [Show full text]
  • MENEST ® Brand of Esterified Estrogens Tablets, USP
    PRESCRIBING INFORMATION MENEST ® brand of esterified estrogens tablets, USP WARNINGS 1. ESTROGENS HAVE BEEN REPORTED TO INCREASE THE RISK OF ENDOMETRIAL CARCINOMA. Three independent case control studies have shown an increased risk of endometrial cancer in postmenopausal women exposed to exogenous estrogens for prolonged periods.1–3 This risk was independent of the other known risk factors for endometrial cancer. These studies are further supported by the finding that incidence rates of endometrial cancer have increased sharply since 1969 in eight different areas of the United States with population-based cancer reporting systems, an increase which may be related to the rapidly expanding use of estrogens during the last decade.4 The three case control studies reported that the risk of endometrial cancer in estrogen users was about 4.5 to 13.9 times greater than in nonusers. The risk appears to depend on both duration of treatment1 and on estrogen dose.3 In view of these findings, when estrogens are used for the treatment of menopausal symptoms, the lowest dose that will control symptoms should be utilized and medication should be discontinued as soon as possible. When prolonged treatment is medically indicated, the patient should be reassessed on at least a semiannual basis to determine the need for continued therapy. Although the evidence must be considered preliminary, one study sug- gests that cyclic administration of low doses of estrogen may carry less risk than continuous administration3; it therefore appears prudent to utilize such a regimen. Close clinical surveillance of all women taking estrogens is important. In all cases of undiagnosed persistent or recurring abnormal vaginal bleeding, adequate diagnostic measures should be undertaken to rule out malignancy.
    [Show full text]
  • Steroids 78 (2013) 44–52
    Steroids 78 (2013) 44–52 Contents lists available at SciVerse ScienceDirect Steroids journal homepage: www.elsevier.com/locate/steroids Alternative long-term markers for the detection of methyltestosterone misuse ⇑ C. Gómez a,b, O.J. Pozo a, J. Marcos a,b, J. Segura a,b, R. Ventura a,b, a Bioanalysis Research Group, IMIM-Hospital del Mar, Barcelona, Spain b Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain article info abstract Article history: Methyltestosterone (MT) is one of the most frequently detected anabolic androgenic steroids in doping Received 21 May 2012 control analysis. MT misuse is commonly detected by the identification of its two main metabolites Received in revised form 28 September excreted as glucuronide conjugates, 17a-methyl-5a-androstan-3a,17b-diol and 17a-methyl-5b-andro- 2012 stan-3a,17b-diol. The detection of these metabolites is normally performed by gas chromatography–mass Accepted 10 October 2012 spectrometry, after previous hydrolysis with b-glucuronidase enzymes, extraction and derivatization Available online 2 November 2012 steps. The aim of the present work was to study the sulphate fraction of MT and to evaluate their potential to improve the detection of the misuse of the drug in sports. MT was administered to healthy volunteers Keywords: and urine samples were collected up to 30 days after administration. After an extraction with ethyl ace- Methyltestosterone Sulphate tate, urine extracts were analysed by liquid chromatography tandem mass spectrometry using electro- Metabolism spray ionisation in negative mode by monitoring the transition m/z 385 to m/z 97. Three diol sulphate LC–MS/MS metabolites (S1, S2 and S3) were detected.
    [Show full text]
  • Estradiol-17Β Pharmacokinetics and Histological Assessment Of
    animals Article Estradiol-17β Pharmacokinetics and Histological Assessment of the Ovaries and Uterine Horns following Intramuscular Administration of Estradiol Cypionate in Feral Cats Timothy H. Hyndman 1,* , Kelly L. Algar 1, Andrew P. Woodward 2, Flaminia Coiacetto 1 , Jordan O. Hampton 1,2 , Donald Nickels 3, Neil Hamilton 4, Anne Barnes 1 and David Algar 4 1 School of Veterinary Medicine, Murdoch University, Murdoch 6150, Australia; [email protected] (K.L.A.); [email protected] (F.C.); [email protected] (J.O.H.); [email protected] (A.B.) 2 Faculty of Veterinary and Agricultural Sciences, University of Melbourne, Melbourne 3030, Australia; [email protected] 3 Lancelin Veterinary Hospital, Lancelin 6044, Australia; [email protected] 4 Department of Biodiversity, Conservation and Attractions, Locked Bag 104, Bentley Delivery Centre 6983, Australia; [email protected] (N.H.); [email protected] (D.A.) * Correspondence: [email protected] Received: 7 September 2020; Accepted: 17 September 2020; Published: 21 September 2020 Simple Summary: Feral cats (Felis catus) have a devastating impact on Australian native fauna. Several programs exist to control their numbers through lethal removal, using tools such as baiting with toxins. Adult male cats are especially difficult to control. We hypothesized that one way to capture these male cats is to lure them using female cats. As female cats are seasonal breeders, a method is needed to artificially induce reproductive (estrous) behavior so that they could be used for this purpose year-round (i.e., regardless of season).
    [Show full text]
  • Drug and Chemical Reference Guideline
    WISCONSIN DEPARTMENT OF AGRICULTURE, TRADE AND CONSUMER PROTECTION DIVISION OF FOOD AND RECREATIONAL SAFETY TITLE: Drug and Chemical Reference Guideline Document #: Replaces: New Revision Date: 1/21/2020 Page 1 of 6 General Guidelines: These drugs and substances are not to be used or • Drugs and administration equipment stored to not stored on dairy farms. These drugs are not eligible for contaminate milk or milk contact surfaces ELU privileges by veterinarians. • Non-lactating drugs separated from lactating drugs • Chloramphenicol using separate shelves or cabinets • Clenbuterol • Drugs properly labeled (see label requirements • Colloidal Silver below) • Diethylstilbestrol (DES) • Locked drug cabinets must be made accessible for • Dimethysulfoxide (DMSO) inspection • Dimetridazole • Drugs for animal species other than cattle must not • Dipyrone (Novine, No Pain) be stored in dairy facility • Estradiol Cypionate (ECP) • All bottles or packages in case lots properly labeled • Fluoroquinolones (sarafloxacin-Saraflox, orbafloxacin-Orbox, danofloxacin mesylate-A 180) Drug Labeling Requirements: • Furazolidone, Nitrofurazone, other Nitrofurans OTC Drugs: (over the counter) • Glycopeptides (vancomycin) • Name of Drug • Iononphores (Lasalocid) permitted for non-lactating • Active ingredients • Ipronidazole • Directions for use • Metronidazole and other Nitroimidazoles • Withholding/withdrawal or discard time for meat or • Phenylbutazone, “bute” (prohibited in dairy animals milk (even if zero) 20 months of age or older - no ELU allowed.) • Name
    [Show full text]
  • Estrogen Agents, Oral-Transdermal
    GEORGIA MEDICAID FEE-FOR-SERVICE ESTROGEN AGENTS, ORAL - TRANSDERMAL PA SUMMARY Preferred Non-Preferred Oral Estrogens Estradiol generic n/a Menest (esterified estrogens) Premarin (estrogens, conjugated) Oral Estrogen/Progestin Combinations Angeliq (drospirenone/estradiol) Bijuva (estradiol/progesterone) Estradiol/norethindrone and all generics for Activella Norethindrone/ethinyl estradiol and all generics for Femhrt Low Dose 0.5/2.5 (norethindrone/ethinyl Femhrt Low Dose estradiol) Jinteli and all generics for Femhrt 1/5 (norethindrone/ethinyl estradiol) Prefest (estradiol/norgestimate) Premphase (conjugated estrogens/medroxyprogesterone) Prempro (conjugated estrogens/medroxyprogesterone) Topical Estrogens Alora (estradiol transdermal patch) Divigel (estradiol topical gel) Estradiol transdermal patch (generic Climara) Elestrin (estradiol topical gel) Evamist (estradiol topical spray solution) Estradiol transdermal patch (generic Vivelle-Dot) Menostar (estradiol transdermal patch) Minivelle (estradiol transdermal patch) Vivelle-Dot (estradiol transdermal patch) Topical Estrogens/Progestin Combination Climara Pro (estradiol/levonorgestrel transdermal patch) n/a Combipatch (estradiol/norethindrone transdermal patch) Oral Selective Estrogen Receptor Modulator (SERMs) Raloxifene generic Duavee (conjugated estrogens/bazedoxifene) Osphena (ospemifene) LENGTH OF AUTHORIZATION: 1 year PA CRITERIA: Bijuva ❖ Approvable for the treatment of moderate to severe vasomotor symptoms associated with menopause in women with an intact uterus who have experienced inadequate response, allergies, contraindications, drug-drug interactions or intolerable side effects to at least two preferred oral estrogen/progestin combination products. Revised 6/29/2020 Norethindrone/Ethinyl Estradiol and All Generics for Femhrt Low Dose ❖ Prescriber must submit a written letter of medical necessity stating the reasons at least two preferred oral estrogen/progestin combination products, one of which must be brand Femhrt Low Dose, are not appropriate for the member.
    [Show full text]
  • Degradation of Doping-Relevant Steroids by Rh. Erythropolis
    In: W Schänzer, H Geyer, A Gotzmann, U Mareck (eds.) Recent Advances In Doping Analysis (15). Sport und Buch Strauß - Köln 2007 J. Grosse1), C. Rautenberg1), L. Wassill2), D. Ganghofner2), D. Thieme3) Degradation of doping-relevant Steroids by Rh. Erythropolis 1) Institute of Doping Analysis and Sports Biochemistry, D-01731 Kreischa, Germany 2) Amplex Diagnostics GmbH, D-80337 Munich, Germany 3) Institute of Legal Medicine, D-80337 Munich, Germany Introduction Former studies have shown that steroids are potential substrates for microorganisms [1]. As an example, the degradation of testosterone induced by Rhodococcus erythropolis was observed. The formation of 4-androstene-3,17-dione, 1,4-androstadiene-3,17-dione (boldione) and 1,4-androstadiene-17β-hydroxy-3-one (boldenone) was confirmed [2]. Consequently a potential endogenous origin of boldenone and its metabolites has to be taken into consideration for the evaluation of routine doping control samples revealing the presence of these substances at low concentration level [3, 4]. This work presents results obtained from further studies related to the microbial conversion of steroid substrates being relevant in doping analysis. For this purpose incubation by Rh. erythropolis was applied to examine the influence of structural variations (A/B-ring structure, substitution at position 17, conjugation) on the initial steps of the degradation pathway. Experimental Rh. erythropolis culture grown on agar plate “Mueller-Hinton” was utilised. Altogether 16 substrates (see table 1) were examined in this study. The experiments were carried out in a blank urine of a male infant spiked with 1 µg/mL of the selected substrate. Two aliquots of each sample were prepared, one control without addition and one „active“ sample with addition of bacteria solution, and incubated at 30°C for 24 hours.
    [Show full text]
  • Determination of 17 Hormone Residues in Milk by Ultra-High-Performance Liquid Chromatography and Triple Quadrupole Mass Spectrom
    No. LCMSMS-065E Liquid Chromatography Mass Spectrometry Determination of 17 Hormone Residues in Milk by Ultra-High-Performance Liquid Chromatography and Triple Quadrupole No. LCMSMS-65E Mass Spectrometry This application news presents a method for the determination of 17 hormone residues in milk using Shimadzu Ultra-High-Performance Liquid Chromatograph (UHPLC) LC-30A and Triple Quadrupole Mass Spectrometer LCMS- 8040. After sample pretreatment, the compounds in the milk matrix were separated using UPLC LC-30A and analyzed via Triple Quadrupole Mass Spectrometer LCMS-8040. All 17 hormones displayed good linearity within their respective concentration range, with correlation coefficient in the range of 0.9974 and 0.9999. The RSD% of retention time and peak area of 17 hormones at the low-, mid- and high- concentrations were in the range of 0.0102-0.161% and 0.563-6.55% respectively, indicating good instrument precision. Method validation was conducted and the matrix spike recovery of milk ranged between 61.00-110.9%. The limit of quantitation was 0.14-0.975 g/kg, and it meets the requirement for detection of hormones in milk. Keywords: Hormones; Milk; Solid phase extraction; Ultra performance liquid chromatograph; Triple quadrupole mass spectrometry ■ Introduction Since 2008’s melamine-tainted milk scandal, the With reference to China’s national standard GB/T adulteration of milk powder has become a major 21981-2008 "Hormone Multi-Residue Detection food safety concern. In recent years, another case of Method for Animal-derived Food - LC-MS Method", dairy product safety is suspected to cause "infant a method utilizing solid phase extraction, ultra- sexual precocity" (also known as precocious puberty) performance liquid chromatography and triple and has become another major issue challenging the quadrupole mass spectrometry was developed for dairy industry in China.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]